Description

IL-27 is a heterodimeric cytokine consisting of EBV-induced gene-3 (EBI3, an IL-12 p40-related protein) and p28 (a newly discovered IL-12 P35-related protein). It is a member of the IL-6/IL-12 cytokine family and mainly produced by antigen-presenting cells, including macrophages and dendritic cells. IL-27 acts on T cells and NK cells. It has been reported that IL-27 drives rapid clonal expansion of naïve CD4⁺ T cells, and promotes Th1 polarization and IFN-γ production in synergy with IL-12. The IL-27-induced Th1 differentiation was mediated by rapid and marked upregulation of ICAM-1/LFA-1 interaction in a STAT1-dependent manner. IL-27 exhibits anti-inflammatory function by enhancing Th1 cell differentiation, a potent antitumor activity, through CD8⁺ T cell and NK cell activation. It also plays a potential therapeutic role in autoimmune disease by inhibiting Th-17 development. IL-27 mediates its biological effects through its receptor, WSX-1/T cell cytokine receptor (TCCR), which is homologous to the IL-12Rβ2 subunit. Protein gp130 serves as a functional signal-transducing molecule for IL-27.

Formulation

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

References

1. Uyttenhove C, et al. 2011. J. Leuko. Biol. 89:1001.